Evidence map›Paper›PMID 36535780›Full record

ArticleNeurology2023

Association Between Frailty and Antiseizure Medication Tolerability in Older Adults With Epilepsy.

Arielle Vary-O'Neal, Sareh Miranzadeh, Nafisa Husein, Jayna Holroyd-Leduc, Tolulope T Sajobi, Samuel Wiebe, Charles Deacon, Jose Francisco Tellez-Zenteno, Colin Bruce Josephson, Mark R Keezer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Arielle Vary-O'NealFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.
Sareh MiranzadehFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.
Nafisa HuseinFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.
Jayna Holroyd-LeducFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.ORCID 0000-0002-4120-0792
Tolulope T SajobiFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.ORCID 0000-0002-5696-5552
Samuel WiebeFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.ORCID 0000-0002-1061-9099
Charles DeaconFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.
Jose Francisco Tellez-ZentenoFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.ORCID 0000-0003-1711-7873
Colin Bruce JosephsonFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada.ORCID 0000-0001-7052-1651
Mark R KeezerFrom the Centre de Recherche du Centre hospitalier de l'Université de Montréal (crCHUM) (A.V., N.H., M.R.K.), Canada; Department of Neurosciences (A.V., M.R.K.), Université de Montréal, Canada; Division of Neurology (S.M., J.T.), University of Saskatchewan, Canada; School of Public Health of the Université de Montréal (N.H., M.R.K.), Canada; Department of Medicine, University of Calgary (J.H.), Canada; Department of Clinical Neurosciences and Hotchkiss Brain Institute (T.T.S., S.W., C.B.J.), University of Calgary, Canada; and Division of Neurology (C.D.), Centre Hospitalier Universitaire de Sherbrooke (CHUS), Canada. mark.keezer@umontreal.ca.ORCID 0000-0002-2807-7347
Centre Hospitalier de l’Université de Montréal · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveFrailty is an important aspect of biological aging, referring to the increased vulnerability of individuals with frailty to physical and psychological stressors. While older adults with epilepsy are an important and distinct clinical group, there are no data on frailty in this population. We hypothesize that frailty will correlate with the seizure frequency and especially the tolerability of antiseizure medications (ASMs) in older adults with epilepsy.

methodsWe recruited individuals aged 60 years or older with active epilepsy from 4 Canadian hospital centers. We reported the seizure frequency in the 3 months preceding the interview, while ASM tolerability was quantified using the Liverpool Adverse Events Profile (LAEP). We applied 3 measures of frailty: grip strength as a measure of physical frailty, 1 self-reported score (Edmonton frail score [EFS]), and 1 scale completed by a healthcare professional (clinical frailty scale [CFS]). We also administered standardized questionnaires measuring levels of anxiety, depression, functional disability, and quality of life and obtained relevant clinical and demographic data.

resultsForty-three women and 43 men aged 60-93 years were recruited, 87% of whom had focal epilepsy, with an average frequency of 3.4 seizures per month. Multiple linear regression and zero-inflated negative binomial regression models showed that EFS and CFS scores were associated with decreased ASM tolerability, each point increase leading to 1.83 (95% CI: 0.67-4.30) and 2.49 (95% CI: 1.27-2.39) point increases on the LAEP scale, respectively. Neither the EFS and CFS scores nor grip strength were significantly associated with seizure frequency. The EFS was moderately correlated with depression, anxiety, quality of life, and functional disability, demonstrating the best construct validity among the 3 tested measures of frailty. DISCUSSION: The EFS was significantly, both statistically and clinically, associated with ASM tolerability. It also showed multiple advantages in performance while assessing for frailty in older adults with epilepsy, when compared with the 2 other measures of frailty that we tested. Future studies must focus on what role the EFS during epilepsy diagnosis may play in ASM selection among older adults with epilepsy.

Indexed as

EpilepsyFrailtyAgedCanadaFemaleHumansMaleQuality of LifeSeizures

Identifiers

PMID36535780
PMCPMC10074467
OpenAlexW4312019230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.